Quillivant Oral Suspension XR

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Attention Deficit Hyperactivity Disorder

Drug Information

Target Indication

Attention Deficit Hyperactivity Disorder

Clinical Trial

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Related Pipeline

Vaccines, Pneumococcal

Renal Transplantation

Diabetes Mellitus

Major Depressive Disorder

Complicated Intra-abdominal Infections